EP0060129A2 - Vaccines, a method for making vaccines and a method for stimulating antibody production - Google Patents

Vaccines, a method for making vaccines and a method for stimulating antibody production Download PDF

Info

Publication number
EP0060129A2
EP0060129A2 EP82301181A EP82301181A EP0060129A2 EP 0060129 A2 EP0060129 A2 EP 0060129A2 EP 82301181 A EP82301181 A EP 82301181A EP 82301181 A EP82301181 A EP 82301181A EP 0060129 A2 EP0060129 A2 EP 0060129A2
Authority
EP
European Patent Office
Prior art keywords
genes
pathogenic microorganism
plasmid
vaccine
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP82301181A
Other languages
German (de)
French (fr)
Other versions
EP0060129A3 (en
EP0060129B1 (en
Inventor
Walter Southwick Dallas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Priority to AT82301181T priority Critical patent/ATE47961T1/en
Publication of EP0060129A2 publication Critical patent/EP0060129A2/en
Publication of EP0060129A3 publication Critical patent/EP0060129A3/en
Application granted granted Critical
Publication of EP0060129B1 publication Critical patent/EP0060129B1/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates generally to the field of immunology and, more particularly, to an improved vaccine for prevention of gastro-enteric disease.
  • the invention also relates to an improved method of stimulating antibody production in a manmalian species using such a vaccine and to an improved method for producing such a vaccine.
  • a further problem with many pathogens is that created by so-called capsular antigens. These polysaccharide layers cause alteration in the surface antigens exposed to potential antibody reaction Consequently, a set of antibodies stimulated by one type of vaccine may be ineffective against the same pathogen with altered surface characteristics resulting from capsular antigens. This, as well as the other problems mentioned above, add cost and complexity to the manufacture of vaccines in this way.
  • Vaccines have, as mentioned above, been developed using purified pili which are capable of causing an antibody response in a vaccinated host.
  • purification of the desired substance can be an exceedingly difficult and expensive procedure, greatly increasing the cost of such vaccines.
  • the present invention enables the provision of a vaccine comprising a non-pathogenic microorganism and employing toxoids and/or adhesins as the antigenic determinants without requiring purification and isolation of such substances.
  • the vaccine of the invention comprises a non-pathogenic microorganism strain containing stable replicative plasmids, each having a gene or genes non-indigenous to the plasmid.
  • the genes are either genes for an adhesin necessary for adherence of the pathogenic microorganism in the mammalian species, or genes for toxoids of a toxin causative of the disease. Combinations of the two types of genes are also possible.
  • the invention takes advantage of the newly emerging technology of recombinant DNA.
  • microorganisms can be genetically engineered which are harmless but which make a protein product which stimulates production of desired antibodies.
  • the genes which are inserted into the host microorganism are inserted by means of plasmid cloning vectors.
  • the genes are either genes for an adhesin necessary for adherence of the pathogenic microorganism being vaccinated against, or genes for toxoids of a toxin causative of the disease. In some cases, both types of genes will be used.
  • the non-pathogenic host in which the genes have been inserted manufactures the proteins encoded by those genes, thus enabling the vaccinated subject to produce antibodies in response to such proteins. These antibodies will then confer immunity against all other microorganism species which manufacture those proteins including, of course, pathogenic species.
  • adhesins there are four known K88 types, ab, ac, ad and ad(e). K88(ac) and K99 have been cloned successfully. These adhesins are factors in neonatal diarrhea in piglets, calves and lambs. They have also been proven to be the important immunogen antigenically determinant in provoking the protective response. Jones, G. W. and Rutter, J. M., Am. J. of Clin. Nutr., 27:1441-1449 (Dec. 1974); Guinee, P. A. M., Veldkamp, J., and Jansen, W. H., Infect. Immun. 15:676-678 (1977).
  • the gene for the heat labile toxin LT has been cloned, So, M., Dallas, W. S., Falkow, S., Infect. Immun., 21:405-411 (1978). Also, the gene for one subunit of LT, LT-B, a non-deleterious part of the toxin, has been cloned. LT-B has been sbown to be determinant in stimulating the antibody response to the toxin LT.
  • LT has been demonstrated to be very similar to the toxin responsible for human cholera, Clements, J. D ., and Finkelstein, R. A., Infect. Immun. 22:709-713 (1978); Gyles, C., Infect. Immun. 9:564-569 (1974); Dallas, W. S.; and Falkow, S., Nature 288:499-501.
  • LT-B can be successfully employed .n live non-pathogenic microorganisms as a vaccine for this disease as well as for many of the E. coli produced diseases.
  • Diarrheal disease in piglets is often caused by E. coli that produce two types of enterotoxins, LT (heat labile toxin) and ST (heat stable toxin). Both of these toxins are plasmid mediated. Gyles, C., So, M., and Falkow, S. J. Infect. Dis. 130:40-49 (1974). E. coli strains producing such toxins frequently have a surface antigen composed of identical subunits that form filamentous surface appendages or pili and which give the pathogenic strain its adhesive properties for the epithelial cells of the upper intestine. Jones, G . W . and R utter, J. M. Infect. Immun. 6:918-927 (1972). A form of this antigen, K88, exists in at least four serologically distinguishable varieties known as K88ab, K88ac, K88ad and K88ad(e).
  • K88ac The K88 gene (K88ac) was first cloned at the University of Washington in Seattle. Shipley, P. L., D allas, W. S., Dougan, G., and Falkow, S. Microbiology, 1979 (American Society for Microbiology, p. 176-180). Although the specific technique has not been published, it is essentially a standard cloning technique.
  • the plasmid pPS100 which is 90Kb in size, is cleaved with the restriction enzyme HindIII.
  • a 7.8Kb DNA fragment, that includes the K88 gene, is inserted into the HindIII site in the plasmid pB R 322, producing a plasmid 12.1Kb in size, designated pPS002.
  • This plasmid retains a functional gene for resistance to ampicillin (Amp R ) which enables the direct selection for transformants of E. coli K-12 harboring the plasmid.
  • Tet S tetracycline sensitivity
  • K99 is a similar adhesin or pili which is responsible for a certain amount of enteric disease in pigs, and for a relatively larger amount of enteric disease in lambs and calves.
  • protocols are used essentially identical to those followed in Example I in connection with K88.
  • the plasmid used was designated pBR313 ( T et A mp ) and selection was for Amp, T et , and agglutination with K99 antibody.
  • the result was a plasmid pwD010 (15:45Kb).
  • the vaccine may be utilized in the live state, or may be attenuated or killed in accordance with known procedures. Vaccination results may be successfully achieved by subcutaneous injections of pregnant sows, ewes, or cows, six weeks, and again at four weeks, prior to farrowing using a single subcutaneous injection each time.
  • the plasmids constructed in Example I containing the K88 genes were designated pPS002.
  • the plasmid of Example II, pWD010, containing the K99 gene was derived from the plasmid pBR313. Since the plasmid p P S002 containing the K88 genes was derived from the plasmid pBR322, both plasmids pPS002 and pWD010 belong to the same incompatibility group. Only plasmids which are members of different incompatibility groups can stably exist together.
  • the K99 gene of pWD010 was cloned as a BamH-I fragment into a tetracycline resistance (Tet R ) gene of a plasmid designated pACYC184, producing a plasmid designated pCTS3002 (10.65Kb).
  • This plasmid confers chloramphenicol resistance (CM R ), to cells and has lost the function of its T et R gene (Tet S ), and produces K99.
  • CM R chloramphenicol resistance
  • T et S T et R gene
  • Transformation of E. coli K12 with these two plasmids resulted in cells which produced both K88 and K99, although instability was noted after a time. Such transformants may be utilized as described above in vaccination procedures.
  • This example relates to the utilization of a single plasmid containing both the gene for K88 and the gene for K99.
  • the composite plasmid designated pWD600, was 22.2Kb in size and conferred chloramphenicol resistance (CM R ) and both K88 and K99 expression to the host cell. It was created by inserting the HindIII fragment including the K88 gene from pPS002 (12.1 Kb Amp R , K88+) being inserted into plasmid pCTS3002 (10.65Kb, CM R , K99+).
  • HindIII treatment of plasmid pCTS3002 was followed by alkaline phosphate treatment to prevent the plasmid from recircularizing on itself in the presence of T4 DNA ligase.
  • the composite plasmid produced both antigens as assessed by agglutination tests, but the level of antigen production was lower than with each gene in a separate bacterium. However, the plasmid was stable and production continued.
  • strains containing this composite plasmid may be utilized as described above in vaccination procedures.
  • the L T gene was cloned from the plasmid p307 as described by So, M ., Dallas, W. S., and Falkow, S., Infect. Immun. 21:405-411 (1978). A further series of steps produces the plasmid EWD299 as described in Dallas, W. S., Gill, D . M., Falkow, S., J. Bacteriol. 139:850-858 (1979).
  • the cistron that encodes for the B subunit of LT was then cloned individually into the expression vector pJJS500 by cleaving EW D 299 with EcoRI and ligating this DNA to EcoRI cleaved pJJ S 500.
  • a plasmid was identified which specified LT-B production but no LT-A production and was designated EWD1000.
  • the LT-B cistron is being transcribed from the UV5 lac promoter in this plasmid.
  • Assays indicate 10-20% greater production of LT-B in the non-pathogenic strain compared to the pathogenic wild type strain.
  • pJJS500 also is known to contain a gene for the surface antigen of Hepatitis B. This surface antigen, however, is not expressed and therefore will not be present in a final product. However, it may be desired to totally eliminate the gene for the Hepatitis B surface antigen.
  • the plasmid pJJS500 is cut by the restriction enzyme HindIII and BamH-I to remove all of the gene for L-TB as well as the gene for the UV5 lac promoter. This fragment is then inserted into the plasmid pPM31 by inserting at the HindIII-BamH-I gap created after appropriate removal of this fragment from the pPM31. The resulting plasmid is Tet (because part of the gene for tetracycline resistance is removed with the HindIII-BamH-I fragment). The plasmid is also absent for the gene for the Heptatits B antigen.
  • LT-B and K88 have been produced in the same host from the two different plasmids pPS002 and EwD1000, as created in Examples I and V above. These composite plasmids are of different compatibility groups and so are stable in the same host. The antigen production is similar to previously discussed results.
  • genes for antibiotic resistance be eliminated from the plasmids utilized. It is preferable to not have resistant genes in vaccines and these may be replaced by genetic elements, conferring the ability on the microorganisms constitutive expression of enzymes necessary for lactose utilization, allowing easy identification of bacteria with the recombinant plasmids.
  • the invention provides improved vaccines and an improved vaccination procedure in which live or attenuated or killed non-pathogenic microorganisms are used.
  • live or attenuated or killed non-pathogenic microorganisms are used.
  • other toxins produced by the microorganisms, or other disease-carrying factors are not present in the vaccine.
  • a vaccine which is live and which contains a suitable adhesin factor along with the non-toxic antigenic determinant for a gastroenteric toxin could permanently colonize in the gastrointestinal tract, conferring long lasting immunity.
  • the invention includes, of course, a method for making a vaccine against gastorenteric disease caused in a mammalian species by a pathogenic microorganism, which method comprises introducing into a non- pathogenic microorganism strain stable replicative plasmids each having a gene or genes non-indigenous to the plasmid and selected from genes for an adhesin necessary for the adherence of the pathogenic microorganism in the mammalian species and/or genes for toxoids of a toxin causative of the disease.
  • the invention also includes a method for stimulating in a member of a mammalian species the production of antibodies against pathogens associated with gastroenteric disease caused by a pathogenic microorganism, which method comprises challenging said member with a non-pathogenic microorganism strain containing stable replicative plasmids each having a gene or genes non-indigenous to the plasmid and selected from genes for an adhesin necessary for the adherence of the pathogenic microorganism in the mammalian species and/or genes for toxoids of a toxin causative of the disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A vaccine is described for prevention of gastroenteric disease caused in a mammalian species by a pathogenic microorganism and which avoids, in its manufacture, the use of pathogens (which must be attenuated or killed) and the attendant risks, costs and complexity. The present vaccine comprises a nonpathogenic microorganism strain containing stable replicative plasmids, each having one or more genes non-indigenous to the plasmid. The non-indigenous genes are either genes for an adhesin necessary for adherence of the pathogenic microorganism in the mammalian species or are genes for toxoids of toxins causative of the disease. Both types of genes may also be included in the same plasmid.
The invention includes the method of manufacture of such vaccines and their use in stimulating the production of antibodies.

Description

  • This invention relates generally to the field of immunology and, more particularly, to an improved vaccine for prevention of gastro-enteric disease. The invention also relates to an improved method of stimulating antibody production in a manmalian species using such a vaccine and to an improved method for producing such a vaccine.
  • Many gastro-enteric diseases in humans and animals, such as those caused by Escherichia coli and similar bacteria, are generally the result of toxin production which operates to disrupt the fluid balance in the gastro-intestinal tract. The result is excessive production of fluids and electrolytes from the epithelial cells in the gastro-intestinal tract. (Moon, H. W., Adv. Vet. Sci. and Compt. Med., 18:179-211 (1974).) By way of example, certain strains of E. coli cause a cholera-like disease in humans and young farm animals which may result from the action of either of two toxins that have been isolated and identified as ST, which is heat stable, and LT, which is heat labile. Kohler, E. M., Am. J. Vet. Res. 29:2263-2274, (1968); Gyles, C. L. & Barnum, D. A., J. Inf. Dis. 120:419-426 (1968).
  • Recent studies have shown that in order for pathogens to successfully colonize parts of the body, it - is necessary for the pathogen to have the ability to adhere to the cell surfaces so that it can multiply. After colonization, the pathogens produce agents, such as toxins, which cause the undesirable symptoms. Science 209:1103-1106, Sept. 1980. The adhesins necessary for this adherence are typically structures called pili, which are thread-like projections on bacterial cell surfaces and are typically necessary if the pathogen is to cause disease.
  • It has been established that immunity to pathogens can be conferred by immunizing against the toxins which they produce; Dobrescu, L., and Huygelen, C., Zpl. Det. Med. B, 23:79-88 (1976), and by immunizing against the adhesin factor, Jones, G. W., and Rutter, J. M., Am. J. of Clinical Nutrition, 27:1441-1449, (Dec. 1974); Nagy, B., Infect. Immun., 27:21-24, (Jan. 1980). Vaccines conferring such immunities have been prepared with killed pathogens which themselves contained genes for producing the offending substances. In addition, vaccines have been prepared using the pure adhesin itself.
  • Preparation of vaccines in the ways referred to above leads to a number of serious problems. If the pathogen itself is used, the pathogen must be attenuated or killed in order to avoid causing the infection which the vaccination is designed to prevent. Of course, this requires a high degree of quality control in the manufacture of the vaccine to ensure proper attenuation or killing of the pathogen. Moreover, manufacturing vaccines of this type in this way necessitates providing growth conditions for large amounts of pathogens which, in the case of human diseases, are potential infectants of the human beings associated with the manufacturing process. Additionally, great care must be taken to insure that the live pathogens do not escape to the surrounding environment.
  • A further problem with many pathogens is that created by so-called capsular antigens. These polysaccharide layers cause alteration in the surface antigens exposed to potential antibody reaction Consequently, a set of antibodies stimulated by one type of vaccine may be ineffective against the same pathogen with altered surface characteristics resulting from capsular antigens. This, as well as the other problems mentioned above, add cost and complexity to the manufacture of vaccines in this way.
  • Vaccines have, as mentioned above, been developed using purified pili which are capable of causing an antibody response in a vaccinated host. Morgan, R. L., Isaacson, R. E., Moon, H. W., and To, C.C. Infect. Immun. 22:771-777 (Dec. 1978). However, purification of the desired substance can be an exceedingly difficult and expensive procedure, greatly increasing the cost of such vaccines.
  • The present invention enables the provision of a vaccine comprising a non-pathogenic microorganism and employing toxoids and/or adhesins as the antigenic determinants without requiring purification and isolation of such substances.
  • Very generally, the vaccine of the invention comprises a non-pathogenic microorganism strain containing stable replicative plasmids, each having a gene or genes non-indigenous to the plasmid. The genes are either genes for an adhesin necessary for adherence of the pathogenic microorganism in the mammalian species, or genes for toxoids of a toxin causative of the disease. Combinations of the two types of genes are also possible.
  • The invention takes advantage of the newly emerging technology of recombinant DNA. By using such techniques, microorganisms can be genetically engineered which are harmless but which make a protein product which stimulates production of desired antibodies. The genes which are inserted into the host microorganism are inserted by means of plasmid cloning vectors. The genes are either genes for an adhesin necessary for adherence of the pathogenic microorganism being vaccinated against, or genes for toxoids of a toxin causative of the disease. In some cases, both types of genes will be used. In any case, the non-pathogenic host in which the genes have been inserted manufactures the proteins encoded by those genes, thus enabling the vaccinated subject to produce antibodies in response to such proteins. These antibodies will then confer immunity against all other microorganism species which manufacture those proteins including, of course, pathogenic species.
  • In the case of adhesins, there are four known K88 types, ab, ac, ad and ad(e). K88(ac) and K99 have been cloned successfully. These adhesins are factors in neonatal diarrhea in piglets, calves and lambs. They have also been proven to be the important immunogen antigenically determinant in provoking the protective response. Jones, G. W. and Rutter, J. M., Am. J. of Clin. Nutr., 27:1441-1449 (Dec. 1974); Guinee, P. A. M., Veldkamp, J., and Jansen, W. H., Infect. Immun. 15:676-678 (1977). The gene for the heat labile toxin LT has been cloned, So, M., Dallas, W. S., Falkow, S., Infect. Immun., 21:405-411 (1978). Also, the gene for one subunit of LT, LT-B, a non-deleterious part of the toxin, has been cloned. LT-B has been sbown to be determinant in stimulating the antibody response to the toxin LT.
  • LT has been demonstrated to be very similar to the toxin responsible for human cholera, Clements, J. D., and Finkelstein, R. A., Infect. Immun. 22:709-713 (1978); Gyles, C., Infect. Immun. 9:564-569 (1974); Dallas, W. S.; and Falkow, S., Nature 288:499-501. Thus, LT-B can be successfully employed .n live non-pathogenic microorganisms as a vaccine for this disease as well as for many of the E. coli produced diseases.
  • The following examples are given as representative of the invention. However, the claims are intended to encompass all forms of the invention and are not intended to be limited by such examples.
    • Example I
  • Diarrheal disease in piglets is often caused by E. coli that produce two types of enterotoxins, LT (heat labile toxin) and ST (heat stable toxin). Both of these toxins are plasmid mediated. Gyles, C., So, M., and Falkow, S. J. Infect. Dis. 130:40-49 (1974). E. coli strains producing such toxins frequently have a surface antigen composed of identical subunits that form filamentous surface appendages or pili and which give the pathogenic strain its adhesive properties for the epithelial cells of the upper intestine. Jones, G. W. and Rutter, J. M. Infect. Immun. 6:918-927 (1972). A form of this antigen, K88, exists in at least four serologically distinguishable varieties known as K88ab, K88ac, K88ad and K88ad(e).
  • The K88 gene (K88ac) was first cloned at the University of Washington in Seattle. Shipley, P. L., Dallas, W. S., Dougan, G., and Falkow, S. Microbiology, 1979 (American Society for Microbiology, p. 176-180). Although the specific technique has not been published, it is essentially a standard cloning technique.
  • To accomplish this, the plasmid pPS100, which is 90Kb in size, is cleaved with the restriction enzyme HindIII. A 7.8Kb DNA fragment, that includes the K88 gene, is inserted into the HindIII site in the plasmid pBR322, producing a plasmid 12.1Kb in size, designated pPS002. This plasmid retains a functional gene for resistance to ampicillin (AmpR) which enables the direct selection for transformants of E. coli K-12 harboring the plasmid. These transformants are then screened for tetracycline sensitivity (TetS) due to the insertion of a DNA fragment in the HindIII site of pBR322 which inactivates the gene controlling resistance to tetracycline. Tets transformants are then tested for K88 production using K88 antibody. A small (4.8Kb) fragment cut by the restriction enzyme EcoRI may then be removed to make the K88 plasmids less of a handicap to the host cell.
  • In actually reducing this portion of the invention to practice, several positive clones resulted from the screening process. All these clones have the same HindIII fragment, all were identical in observable phenomena, and all synthesized approximately four times as much K88 antigen as a wild type pathogenic strain as determined by radioimmunoassay. Although the cloning vector existed in the host at 10-20 copies per cell, the production of K88 was lower than 10-20 times that of the wild type, probably due to as yet unappreciated physiological controls in the host. These strains may then be used live, or may be attenuated or killed by known vaccination preparation techniques, in a vaccine preparation. Use may be in accordance with any suitable known vaccination technique, but is preferably administered to sows at six weeks, and again at four weeks, prior to farrowing using a single subcutaneous injection each time.
    • Example II
  • K99 is a similar adhesin or pili which is responsible for a certain amount of enteric disease in pigs, and for a relatively larger amount of enteric disease in lambs and calves. In preparing a K99 containing vaccine, protocols are used essentially identical to those followed in Example I in connection with K88. The plasmid used was designated pBR313 (Tet Amp ) and selection was for Amp, Tet , and agglutination with K99 antibody. The result was a plasmid pwD010 (15:45Kb).
  • Once again, the vaccine may be utilized in the live state, or may be attenuated or killed in accordance with known procedures. Vaccination results may be successfully achieved by subcutaneous injections of pregnant sows, ewes, or cows, six weeks, and again at four weeks, prior to farrowing using a single subcutaneous injection each time.
    • Example III
  • It is, of course, possible to create a vaccine by mixing organisms producing K88 with organisms producing K99. However, such a technique involves separate growth of two different types of the organism. For.manufacturing purposes, it may be desirable to produce the two pili factors or adhesins in a single organism. There are two ways of doing this. This example deals with a situation in which a single organism contains two different plasmids, one of which contains the K88 gene and the other of which contains the K99 gene. The immediately following example, Example IV, illustrates the technique utilizing a single plasmid containing both the K88 and K99 gene.
  • The plasmids constructed in Example I containing the K88 genes were designated pPS002. The plasmid of Example II, pWD010, containing the K99 gene was derived from the plasmid pBR313. Since the plasmid pPS002 containing the K88 genes was derived from the plasmid pBR322, both plasmids pPS002 and pWD010 belong to the same incompatibility group. Only plasmids which are members of different incompatibility groups can stably exist together. Accordingly, the K99 gene of pWD010 was cloned as a BamH-I fragment into a tetracycline resistance (TetR) gene of a plasmid designated pACYC184, producing a plasmid designated pCTS3002 (10.65Kb). This plasmid confers chloramphenicol resistance (CMR), to cells and has lost the function of its TetR gene (TetS), and produces K99. The plasmid thus created contains the K99 gene, but belongs to a different incompatibility group from that of the plasmid containing the K88 gene. ]
  • Transformation of E. coli K12 with these two plasmids resulted in cells which produced both K88 and K99, although instability was noted after a time. Such transformants may be utilized as described above in vaccination procedures.
    • Example IV
  • This example, as mentioned above, relates to the utilization of a single plasmid containing both the gene for K88 and the gene for K99. The composite plasmid, designated pWD600, was 22.2Kb in size and conferred chloramphenicol resistance (CMR) and both K88 and K99 expression to the host cell. It was created by inserting the HindIII fragment including the K88 gene from pPS002 (12.1 Kb AmpR, K88+) being inserted into plasmid pCTS3002 (10.65Kb, CMR, K99+). HindIII treatment of plasmid pCTS3002 was followed by alkaline phosphate treatment to prevent the plasmid from recircularizing on itself in the presence of T4 DNA ligase. The composite plasmid produced both antigens as assessed by agglutination tests, but the level of antigen production was lower than with each gene in a separate bacterium. However, the plasmid was stable and production continued.
  • These strains containing this composite plasmid may be utilized as described above in vaccination procedures.
    • Example V
  • The LT gene was cloned from the plasmid p307 as described by So, M., Dallas, W. S., and Falkow, S., Infect. Immun. 21:405-411 (1978). A further series of steps produces the plasmid EWD299 as described in Dallas, W. S., Gill, D. M., Falkow, S., J. Bacteriol. 139:850-858 (1979). The cistron that encodes for the B subunit of LT was then cloned individually into the expression vector pJJS500 by cleaving EWD299 with EcoRI and ligating this DNA to EcoRI cleaved pJJS500. A plasmid was identified which specified LT-B production but no LT-A production and was designated EWD1000. The LT-B cistron is being transcribed from the UV5 lac promoter in this plasmid.
  • Assays indicate 10-20% greater production of LT-B in the non-pathogenic strain compared to the pathogenic wild type strain.
  • It should be noted at this poipt that pJJS500 also is known to contain a gene for the surface antigen of Hepatitis B. This surface antigen, however, is not expressed and therefore will not be present in a final product. However, it may be desired to totally eliminate the gene for the Hepatitis B surface antigen. To do this, the plasmid pJJS500 is cut by the restriction enzyme HindIII and BamH-I to remove all of the gene for L-TB as well as the gene for the UV5 lac promoter. This fragment is then inserted into the plasmid pPM31 by inserting at the HindIII-BamH-I gap created after appropriate removal of this fragment from the pPM31. The resulting plasmid is Tet (because part of the gene for tetracycline resistance is removed with the HindIII-BamH-I fragment). The plasmid is also absent for the gene for the Heptatits B antigen.
    • Example VI
  • LT-B and K88 have been produced in the same host from the two different plasmids pPS002 and EwD1000, as created in Examples I and V above. These composite plasmids are of different compatibility groups and so are stable in the same host. The antigen production is similar to previously discussed results.
  • In all of the foregoing examples, it is desirable that genes for antibiotic resistance be eliminated from the plasmids utilized. It is preferable to not have resistant genes in vaccines and these may be replaced by genetic elements, conferring the ability on the microorganisms constitutive expression of enzymes necessary for lactose utilization, allowing easy identification of bacteria with the recombinant plasmids.
  • It may be seen, therefore, that the invention provides improved vaccines and an improved vaccination procedure in which live or attenuated or killed non-pathogenic microorganisms are used. Thus, other toxins produced by the microorganisms, or other disease-carrying factors, are not present in the vaccine. A vaccine which is live and which contains a suitable adhesin factor along with the non-toxic antigenic determinant for a gastroenteric toxin could permanently colonize in the gastrointestinal tract, conferring long lasting immunity.
  • The invention includes, of course, a method for making a vaccine against gastorenteric disease caused in a mammalian species by a pathogenic microorganism, which method comprises introducing into a non- pathogenic microorganism strain stable replicative plasmids each having a gene or genes non-indigenous to the plasmid and selected from genes for an adhesin necessary for the adherence of the pathogenic microorganism in the mammalian species and/or genes for toxoids of a toxin causative of the disease.
  • The invention also includes a method for stimulating in a member of a mammalian species the production of antibodies against pathogens associated with gastroenteric disease caused by a pathogenic microorganism, which method comprises challenging said member with a non-pathogenic microorganism strain containing stable replicative plasmids each having a gene or genes non-indigenous to the plasmid and selected from genes for an adhesin necessary for the adherence of the pathogenic microorganism in the mammalian species and/or genes for toxoids of a toxin causative of the disease. The use of this method enables the production of antibodies (which may, for example, be isolated from the blood of the treated mammal by conventional techniques)to be achieved using the natural mechanisms of the mammalian body without risk to the health of the mammal. Such antibodies can be a useful product in their own right.
  • Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description.

Claims (10)

1. A vaccine against gastro-enteric disease caused in a mammalian species by a pathogenic microorganism and comprising a non-pathogenic microorganism strain containing stable replicative plasmids each having a gene or genes non-indigenous to the plasmid and selected from genes for an adhesin necessary for the adherence of the pathogenic microorganism in the mammalian species and/or genes for toxoids of a toxin causative of the disease.
2. A vaccine as claimed in Claim 1, wherein said plasmids lack any gene or genes for antibiotic resistance.
3. A vaccine as claimed in claim 1 or claim 2, wherein said plasmids contain the DNA partition fragment.
4. A vaccine as claimed in claim 1, wherein both the pathogenic microorganism and the non- pathogenic microorganism are of the species E. coli and the adhesin is selected from K88, K99 and 987P.
5. A vaccine as claimed in claim 1, wherein both the pathogenic microorganism and the non- pathogenic microorganism are of the species E. coli and the toxoid is LT-B.
6. A vaccine as claimed in claim 1, wherein the disease is cholera and the toxoid is LT-B.
7. A method for stimulating in a member of a mammalian species the production of antibodies against pathogens associated with gastroenteric disease caused by a pathogenic microorganism, which method comprises challenging said member with a non-pathogenic microorganism strain containing stable replicative plasmids each having a gene or genes non-indigenous to the plasmid and selected from genes for an adhesin necessary for the adherence of the pathogenic microorganism in the mammalian species and/or genes for toxoids of a toxin causative of the disease.
8. A method as claimed in claim 7 further defined by the feature (s) of any one of claims 2 to 6.
9. A method for making a vaccine against gastroenteric disease caused in a mammalian species by a pathogenic microorganism, which method comprises introducing into a non-pathogenic microorganism strain stable replicative plasmids each having a gene or genes non-indigenous to the plasmid and selected from genes for an adhesin necessary for the adherence of the pathogenic microorganism in the mammalian species and/or genes for toxoids of a toxin causative of the disease.
10. A method as claimed in claim 9 further defined by the feature(s) of any one of claims 2 to 6.
EP82301181A 1981-03-09 1982-03-08 Vaccines, a method for making vaccines and a method for stimulating antibody production Expired EP0060129B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT82301181T ATE47961T1 (en) 1981-03-09 1982-03-08 VACCINES, PROCESSES FOR THEIR MANUFACTURE AND METHODS FOR ENCOURAGING ANTIBODIES PRODUCTION.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24159481A 1981-03-09 1981-03-09
US241594 1981-03-09

Publications (3)

Publication Number Publication Date
EP0060129A2 true EP0060129A2 (en) 1982-09-15
EP0060129A3 EP0060129A3 (en) 1983-06-01
EP0060129B1 EP0060129B1 (en) 1989-11-15

Family

ID=22911341

Family Applications (1)

Application Number Title Priority Date Filing Date
EP82301181A Expired EP0060129B1 (en) 1981-03-09 1982-03-08 Vaccines, a method for making vaccines and a method for stimulating antibody production

Country Status (9)

Country Link
EP (1) EP0060129B1 (en)
JP (1) JP2554611B2 (en)
AT (1) ATE47961T1 (en)
AU (1) AU559550B2 (en)
CA (1) CA1201076A (en)
DE (1) DE3280019D1 (en)
DK (1) DK172670B1 (en)
NZ (1) NZ199866A (en)
WO (1) WO1982003088A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0087735A2 (en) * 1982-02-25 1983-09-07 Takeda Chemical Industries, Ltd. Recombinant DNA, microorganism transformed therewith and their use
EP0127153A2 (en) * 1983-05-26 1984-12-05 The Wellcome Foundation Limited Bivalent vaccines
WO1985005037A1 (en) * 1984-05-02 1985-11-21 Syn-Tek Ab Adhesin antigens, antibodies and dna fragment encoding the antigen, methods and means for diagnosis and immunization etc.
EP0168322A2 (en) * 1984-07-09 1986-01-15 Praxis Biologics, Inc. Production of the E. coli LT-B enterotoxin subunit
EP0172107A1 (en) * 1984-08-10 1986-02-19 Praxis Biologics, Inc. Immunogenic conjugates of E. coli LT-B enterotoxin subunit and capsular polymers
WO1986004604A1 (en) * 1985-01-31 1986-08-14 Slagteriernes Forskningsinstitut A 987p fimbriae-producing microorganism, a vaccine for the immunization of pigs as well as a method for production of the vaccine
EP0222835A1 (en) * 1985-05-15 1987-05-27 Biotech Australia Pty Ltd Oral vaccines.
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
FR2605017A1 (en) * 1986-10-13 1988-04-15 Solvay Microorganisms containing pili as carrier proteins, pili isolated from these microorganisms and method of excretion of peptides or proteins by means of these pili
EP0264150A1 (en) * 1986-10-13 1988-04-20 Solvay Microorganisms comprising pili as carrier proteins, isolated pili, method for excreting proteins using these pili and their use
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
EP0314224A1 (en) * 1987-10-26 1989-05-03 Akzo N.V. Vaccine against E.coli septicaemia in poultry
EP0080806B1 (en) * 1981-10-22 1989-07-19 Research Corporation Live vaccine and its method of production
JPH01268644A (en) * 1987-04-15 1989-10-26 K Teichmann Reihard Pharmaceutical composition containing antigenic substance
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US5079165A (en) * 1988-06-29 1992-01-07 Praxis Biologics, Inc. Production of the E. coli LT-B enterotoxin subunit in S. typhi
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
US5124153A (en) * 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5137721A (en) * 1981-03-09 1992-08-11 Cetus Corporation Employing strains of E. coli expressing non-indigenous adhesins and toxoids of E. coli
US5162226A (en) * 1987-08-24 1992-11-10 University Of Tennessee Research Corp. (U.T.R.C.) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5308835A (en) * 1984-07-09 1994-05-03 Praxis Biologics, Inc. Production of the E. coli LT-B enterotoxin subunit
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US5654184A (en) * 1988-09-06 1997-08-05 Washington University Oral immunization by transgenic plants
WO1998053082A1 (en) * 1997-05-21 1998-11-26 Daewoong Pharmaceutical Co., Ltd. A recombinant microorganism expressing an antigenic protein, adhesin
US5851533A (en) * 1983-08-30 1998-12-22 Genentech, Inc. Vaccine based on membrane bound proteins and process for making them
US6103243A (en) * 1985-05-15 2000-08-15 Biotechnology Australia Pty, Ltd Oral vaccines
WO2000058476A1 (en) * 1999-03-31 2000-10-05 Mta Állatorvos-Tudományi K.I. A strain suitable for producing a live, orally applicable escherichia coli vaccine for the prevention of postweaning diarrhoea in pigs and the procedure suitable for producing that strain
WO2005074706A1 (en) 2004-02-03 2005-08-18 Universite De Montreal Use of live bacteria for growth promotion in animals
WO2009004002A1 (en) * 2007-07-02 2009-01-08 Sbl Vaccin Ab Hybrid operon for expression of colonization factor (cf) antigens of enterotoxigenic escherichia coli
US7785778B2 (en) 2002-11-25 2010-08-31 University Of Copenhagen Porcine polymorphisms and methods for detecting them

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084522A3 (en) * 1982-01-18 1983-10-19 Sandoz Ag Plasmids and bacteria strains, and method of preparing the same
IT1217303B (en) * 1984-02-01 1990-03-22 Enterovax Res Pty Ltd BACTERIAL STRIPS PARTICULARLY USEFUL FOR THE PRODUCTION OF VACCINES FOR THE TREATMENT OF INTESTINAL AND SIMILAR DISEASES AND METHOD OF GENTIC ENGINEERING FOR THE PRODUCTION OF THE SAID VACCINES
AU619908B2 (en) * 1984-02-01 1992-02-06 Enterovax Research Pty. Ltd. Bacterial strains
ES8705033A1 (en) * 1984-12-04 1987-04-16 Biotech Australia Pty Ltd A cloning vehicle for cloning a large fragment of dna and a vaccine comprising 987p fimbrial protein.
JP2660511B2 (en) * 1985-05-15 1997-10-08 バイオテクノロジ−・オ−ストラリア・ピ−テイ−ワイ・リミテツド Oral vaccine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2282908A1 (en) * 1974-09-02 1976-03-26 Canadian Patents Dev VACCINE AGAINST COLIBACILLOSIS
DE2530275A1 (en) * 1975-07-07 1977-01-27 Max Planck Gesellschaft Salmonella-coli hybrids useful for vaccination - produced by transferring 09.12 determinant salmonella chromosomes to a genetically related recipient strain
EP0001930A2 (en) * 1977-11-08 1979-05-16 Genentech, Inc. Method for polypeptide production involving expression of a heterologous gene, recombinant microbial cloning vehicle containing said gene and bacterial culture transformed by said cloning vehicle
FR2442271A1 (en) * 1978-11-27 1980-06-20 Pasteur Institut VECTOR FOR THE INSERTION OF A PROKARYOTE OR EUKARYOTE GENE, AND EXCRETION OF THE EXPRESSED PROTEIN

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL294835A (en) * 1962-07-19 1900-01-01
US3907987A (en) * 1972-05-25 1975-09-23 Canadian Patents Dev Enteric disease vaccine
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4337314A (en) * 1979-05-23 1982-06-29 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2282908A1 (en) * 1974-09-02 1976-03-26 Canadian Patents Dev VACCINE AGAINST COLIBACILLOSIS
DE2530275A1 (en) * 1975-07-07 1977-01-27 Max Planck Gesellschaft Salmonella-coli hybrids useful for vaccination - produced by transferring 09.12 determinant salmonella chromosomes to a genetically related recipient strain
EP0001930A2 (en) * 1977-11-08 1979-05-16 Genentech, Inc. Method for polypeptide production involving expression of a heterologous gene, recombinant microbial cloning vehicle containing said gene and bacterial culture transformed by said cloning vehicle
FR2442271A1 (en) * 1978-11-27 1980-06-20 Pasteur Institut VECTOR FOR THE INSERTION OF A PROKARYOTE OR EUKARYOTE GENE, AND EXCRETION OF THE EXPRESSED PROTEIN

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 93, 1980, pages 439, no. 234917b, Columbus Ohio (USA). S. L. MOSELAY et al.: "Nucleotide sequence homology between the heat-labile enterotoxin gene of Escherichia coli and Vibrio cholerae deoxyribonuelein acid" & J: BACTERIOL: 1980, 144(1), 444-6 *
CHEMICAL ABSTRACTS, vol. 93, 1980, pages 439, no. 234917b, Columbus Ohio (USA); *
INFECTION AND IMMUNITY, vol. 21, no. 2, August 1978, pages 405-411, American Society for Microbiology, (USA); *
Infection Immunity, 29, 1125-33, 1980 *
JOURNAL OF BACTERIOLOGY, no. 139, no. 3, September 1979, pages 850-858; *
JOURNAL OF BACTERIOLOGY, vol. 145, no. 2, February 1981, pages 920-925. P. L. SHIPLEY et al.: "Identification and cloning of the genetic determinant that encodes for the K88ac adherence antigen" *
JOURNAL OF BACTERIOLOGY, vol. 145, no. 2, February 1981, pages 920-925; *
JOURNAL OF BACTORIOLOGY. *
METHODS IN ENZYMOLOGY, (RECOMBINANT DNA), vol. 68, 1979, pages 245-267; *
MICROBIOLOGY-1979, Edited by D.Schlessinger, pages 233-236, American Society for Microbiology, Washington D.C. (USA); *
NATURE, vol. 242, 20th April 1973, pages 531,532. J.M. RUTTER et al.: "Protection against enteric disease caused by Escherichia coli - a model for vaccination with a virulence determinant" *
NATURE, vol. 242, 20th April 1973, pages 531,532; *
PLASMIDS OF MEDICAL, ENVIRONMENTAL AND COMMERCIAL IMPORTANCE, vol. 1, 26th-28th April 1979, Editors K.N.Timmis and A.Pühler, Developments in Genetics, pages 113-122, Elsevier/North-Holland Biomedical Press, Amsterdam (NL); *

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137721A (en) * 1981-03-09 1992-08-11 Cetus Corporation Employing strains of E. coli expressing non-indigenous adhesins and toxoids of E. coli
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
EP0080806B1 (en) * 1981-10-22 1989-07-19 Research Corporation Live vaccine and its method of production
EP0087735A3 (en) * 1982-02-25 1983-11-16 Takeda Chemical Industries, Ltd. Recombinant dna, microorganism transformed therewith and their use
EP0087735A2 (en) * 1982-02-25 1983-09-07 Takeda Chemical Industries, Ltd. Recombinant DNA, microorganism transformed therewith and their use
EP0127153A3 (en) * 1983-05-26 1987-12-02 The Wellcome Foundation Limited Bivalent vaccines
EP0127153A2 (en) * 1983-05-26 1984-12-05 The Wellcome Foundation Limited Bivalent vaccines
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
US5851533A (en) * 1983-08-30 1998-12-22 Genentech, Inc. Vaccine based on membrane bound proteins and process for making them
US5804198A (en) * 1984-05-02 1998-09-08 Symbicom Aktiebolag Vaccines against disease caused by pathogenic pilus-forming bacteria
US6291649B1 (en) 1984-05-02 2001-09-18 Symbicom Aktiebolag Anti-bodies binding adhesin-derived antigens
WO1985005037A1 (en) * 1984-05-02 1985-11-21 Syn-Tek Ab Adhesin antigens, antibodies and dna fragment encoding the antigen, methods and means for diagnosis and immunization etc.
EP0168322A3 (en) * 1984-07-09 1986-11-20 Praxis Biologics, Inc. Production of the e. coli lt-b enterotoxin subunit
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
WO1986000647A1 (en) * 1984-07-09 1986-01-30 Praxis Biologics, Inc. Production of the e. coli lt-b enterotoxin subunit
US5308835A (en) * 1984-07-09 1994-05-03 Praxis Biologics, Inc. Production of the E. coli LT-B enterotoxin subunit
EP0168322A2 (en) * 1984-07-09 1986-01-15 Praxis Biologics, Inc. Production of the E. coli LT-B enterotoxin subunit
WO1986001228A1 (en) * 1984-08-10 1986-02-27 Praxis Biologics, Inc. Immunogenic conjugates of e. coli lt-b enterotoxin subunit and capsular polymers
EP0172107A1 (en) * 1984-08-10 1986-02-19 Praxis Biologics, Inc. Immunogenic conjugates of E. coli LT-B enterotoxin subunit and capsular polymers
WO1986004604A1 (en) * 1985-01-31 1986-08-14 Slagteriernes Forskningsinstitut A 987p fimbriae-producing microorganism, a vaccine for the immunization of pigs as well as a method for production of the vaccine
US6103243A (en) * 1985-05-15 2000-08-15 Biotechnology Australia Pty, Ltd Oral vaccines
EP0222835A1 (en) * 1985-05-15 1987-05-27 Biotech Australia Pty Ltd Oral vaccines.
EP0222835A4 (en) * 1985-05-15 1988-02-01 Biotech Australia Pty Ltd Oral vaccines.
EP0264150A1 (en) * 1986-10-13 1988-04-20 Solvay Microorganisms comprising pili as carrier proteins, isolated pili, method for excreting proteins using these pili and their use
FR2605017A1 (en) * 1986-10-13 1988-04-15 Solvay Microorganisms containing pili as carrier proteins, pili isolated from these microorganisms and method of excretion of peptides or proteins by means of these pili
JPH01268644A (en) * 1987-04-15 1989-10-26 K Teichmann Reihard Pharmaceutical composition containing antigenic substance
US5162226A (en) * 1987-08-24 1992-11-10 University Of Tennessee Research Corp. (U.T.R.C.) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5124153A (en) * 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5593679A (en) * 1987-10-26 1997-01-14 Akzo Nobel N.V. Poultry vaccine against E. coli air sac inflammation and septicaemia
EP0314224A1 (en) * 1987-10-26 1989-05-03 Akzo N.V. Vaccine against E.coli septicaemia in poultry
US5208024A (en) * 1987-10-26 1993-05-04 Akzo Nv Vaccine against E. coli septicaemia in poultry
US5079165A (en) * 1988-06-29 1992-01-07 Praxis Biologics, Inc. Production of the E. coli LT-B enterotoxin subunit in S. typhi
US5679880A (en) * 1988-09-06 1997-10-21 Washington University Oral immunization by transgenic plants
US5654184A (en) * 1988-09-06 1997-08-05 Washington University Oral immunization by transgenic plants
WO1998053082A1 (en) * 1997-05-21 1998-11-26 Daewoong Pharmaceutical Co., Ltd. A recombinant microorganism expressing an antigenic protein, adhesin
WO2000058476A1 (en) * 1999-03-31 2000-10-05 Mta Állatorvos-Tudományi K.I. A strain suitable for producing a live, orally applicable escherichia coli vaccine for the prevention of postweaning diarrhoea in pigs and the procedure suitable for producing that strain
US7785778B2 (en) 2002-11-25 2010-08-31 University Of Copenhagen Porcine polymorphisms and methods for detecting them
EP1715755A1 (en) * 2004-02-03 2006-11-02 Universite de Montreal Use of live bacteria for growth promotion in animals
EP1715755A4 (en) * 2004-02-03 2009-11-25 Valorisation Rech Ltd Partners Use of live bacteria for growth promotion in animals
WO2005074706A1 (en) 2004-02-03 2005-08-18 Universite De Montreal Use of live bacteria for growth promotion in animals
US7981411B2 (en) 2004-02-03 2011-07-19 Valorisation—Recherche, Limited Partnership Use of live bacteria for growth promotion in animals
US8343751B2 (en) 2004-02-03 2013-01-01 Valorisation—Recherche, Limited Partnership Use of live bacteria for growth promotion in animals
US8679823B2 (en) 2004-02-03 2014-03-25 Valorisation-Recherche, Limited Partnership Use of live bacteria for growth promotion in animals
US9452188B2 (en) 2004-02-03 2016-09-27 Prevtec Microbia Inc. Use of live bacteria for growth promotion in animals
US9861665B2 (en) 2004-02-03 2018-01-09 Prevtec Microbia Inc. Use of UVE bacteria for growth promotion in animals
WO2009004002A1 (en) * 2007-07-02 2009-01-08 Sbl Vaccin Ab Hybrid operon for expression of colonization factor (cf) antigens of enterotoxigenic escherichia coli

Also Published As

Publication number Publication date
ATE47961T1 (en) 1989-12-15
AU559550B2 (en) 1987-03-12
AU8331082A (en) 1982-09-28
EP0060129A3 (en) 1983-06-01
DK172670B1 (en) 1999-05-10
DE3280019D1 (en) 1989-12-21
CA1201076A (en) 1986-02-25
WO1982003088A1 (en) 1982-09-16
DK101982A (en) 1982-09-10
EP0060129B1 (en) 1989-11-15
JP2554611B2 (en) 1996-11-13
JPS57171926A (en) 1982-10-22
NZ199866A (en) 1984-11-09

Similar Documents

Publication Publication Date Title
EP0060129B1 (en) Vaccines, a method for making vaccines and a method for stimulating antibody production
Clements et al. Oral immunization of mice with attenuated Salmonella enteritidis containing a recombinant plasmid which codes for production of the B subunit of heat-labile Escherichia coli enterotoxin
Zhang et al. Protective immunity of a multivalent vaccine candidate against piglet diarrhea caused by enterotoxigenic Escherichia coli (ETEC) in a pig model
Dorman et al. Characterization of porin and ompR mutants of a virulent strain of Salmonella typhimurium: ompR mutants are attenuated in vivo
AU767143B2 (en) Lactobacilli harboring aggregation and mucin binding genes as vaccine delivery vehicles
AU745003B2 (en) Live attenuated vaccines
US5631010A (en) Genetically stable cholera vaccines with deletions of ctxA, recA and attRS1
Kwaga et al. A carAB mutant of avian pathogenic Escherichia coli serogroup O2 is attenuated and effective as a live oral vaccine against colibacillosis in turkeys
Cárdenas et al. Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors
Chopra et al. Cloning and expression of the Salmonella enterotoxin gene
US5837825A (en) Campylobacter jejuni flagellin/Escherichia coli LT-B fusion protein
WO1985003521A1 (en) Bacterial strains
Girón et al. Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic Escherichia coli by ΔaroC, ΔaroD Salmonella typhi vaccine strain CVD 908
EP0931093B1 (en) Helicobacter pylori live vaccine
EP0127153A2 (en) Bivalent vaccines
US5137721A (en) Employing strains of E. coli expressing non-indigenous adhesins and toxoids of E. coli
EP0314224B1 (en) Vaccine against e.coli septicaemia in poultry
Gentry-Weeks et al. Cloning and sequencing of a gene encoding a 21-kilodalton outer membrane protein from Bordetella avium and expression of the gene in Salmonella typhimurium
KR20010099789A (en) Virulence Genes And Proteins, And Their Use
US7163820B1 (en) Escherichia coli strain for an oral vaccine against post-weaning diarrhea in pigs
Sirard et al. A recombinant Bacillus anthracis strain producing the Clostridium perfringens Ib component induces protection against iota toxins
Dougan et al. Molecular analysis of the virulence determinants of enterotoxigenic Escherichia coli isolated from domestic animals: applications for vaccine development
EP0145486A2 (en) Microbiological process
EP1210445B1 (en) Recombinant microorganisms
Dougan Molecular characterization of bacterial virulence factors and the consequences for vaccine design

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LU NL SE

17P Request for examination filed

Effective date: 19821215

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CETUS CORPORATION

ET Fr: translation filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

ITF It: translation for a ep patent filed
AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 47961

Country of ref document: AT

Date of ref document: 19891215

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3280019

Country of ref document: DE

Date of ref document: 19891221

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
ITTA It: last paid annual fee
EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 82301181.2

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

BECH Be: change of holder

Free format text: 960724 *CHIRON CORP.

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Ref country code: FR

Ref legal event code: CD

Ref country code: FR

Ref legal event code: CA

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Free format text: CETUS CORPORATION TRANSFER- CETUS ONCOLOGY CORPORATION * CETUS ONCOLOGY CORPORATION TRANSFER- CHIRON CORPORATION

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL & PARTNER AG

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20010219

Year of fee payment: 20

Ref country code: FR

Payment date: 20010219

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20010220

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20010221

Year of fee payment: 20

Ref country code: CH

Payment date: 20010221

Year of fee payment: 20

Ref country code: AT

Payment date: 20010221

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20010222

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20010305

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20010306

Year of fee payment: 20

BE20 Be: patent expired

Free format text: 20020308 *CHIRON CORP.

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020307

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020307

Ref country code: CH

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020308

Ref country code: LU

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020308

Ref country code: AT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020308

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Effective date: 20020307

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20020308

EUG Se: european patent has lapsed

Ref document number: 82301181.2